News about Market

European Commission Approves Pfizer-BioNTech's XFG-Adapted COVID-19 Vaccine for 2026-27 Season

The European Commission has approved Pfizer and BioNTech's monovalent XFG-adapted COVID-19 vaccine for the 2026–27 vaccination season that authorised for people aged six months and above, is designed to enhance protection against currently circulating SARS-CoV-2 variants and will be supplied across the European Union and selected European countries.

Market | 31/07/2026 | By News Bureau

GSK to Establish New Global R&D Centre in Cambridge to Accelerate Drug Discovery

GSK will establish a 300,000 sq. ft. global R&D centre at the Cambridge Biomedical Campus, bringing together more than 1,000 scientists to accelerate medicines discovery through closer collaboration with leading academic, clinical and biotechnology partners.

Market | 30/07/2026 | By News Bureau

Piramal Pharma Reports Q1 FY27 Results

Piramal Pharma has reported its standalone and consolidated Q1 FY27 financial results, highlighting its performance for the quarter ended June 30, 2026.

Market | 30/07/2026 | By News Bureau |  105

HAB Pharmaceuticals Charts Growth Path, Targets INR 2,500 to 3,000 Crore Revenue by 2030

HAB Pharmaceuticals is expanding its manufacturing and R&D capabilities while strengthening its specialty product portfolio and global regulatory footprint as it targets revenues of INR 2,500–3,000 crore by 2030.

Market | 29/07/2026 | By News Bureau

Glenmark Launches Generic Sugammadex Injection in US

Glenmark has launched generic Sugammadex Injection in the US, a bioequivalent and therapeutically equivalent version of Merck's BRIDION Injection.

Market | 29/07/2026 | By News Bureau

Indoco Remedies Reports Improved Q1 FY27 Revenue and EBITDA

Indoco Remedies reported higher revenue and improved EBITDA in Q1 FY27, supported by the strong performance of its domestic formulations business and steady progress in international formulations and APIs.

Market | 28/07/2026 | By News Bureau

Philogen Resubmits EMA Marketing Application for Melanoma Therapy Nidlegy with Updated Phase 3 Data

Philogen has resubmitted its EMA marketing application for investigational melanoma therapy Nidlegy, supported by updated Phase 3 clinical data demonstrating reduced risk of relapse or death and an extended patient follow-up period.

Market | 28/07/2026 | By News Bureau |  105

Harbour BioMed and Sinopharm Partner to Advance Research and Development

Harbour BioMed and Sinopharm have partnered to establish an innovation Research and Development (R&D) consortium focused on biologics for oncology and immune-mediated diseases.

Market | 28/07/2026 | By News Bureau

Biodeal Pharmaceuticals Concludes Piramal Alternatives Partnership

Biodeal delivered strong revenue growth during the hold period, with EBITDA margins improving alongside continued investment in manufacturing and governance.

Market | 28/07/2026 | By News Bureau |  107

Senores Pharmaceuticals Q1 FY27 Revenue Grows 35.9 Percent YoY to INR 180.2 Crore

Senores Pharmaceuticals reported 35.9 percent Year over Year (YoY) revenue growth to INR 180.2 crore in Q1 FY27, driven by regulated and emerging markets and higher profitability.

Market | 27/07/2026 | By News Bureau |  129